TABLE 1.
Demographic and clinical characteristics of study cohort, stratified by type of conditioning therapy
| HD-TBI Conditioning (n=58) | Non-TBI Conditioning (n=329) | All patients (n=387) | P-value | |
|---|---|---|---|---|
| Median age at diagnosis (range), years | 33 (18-57) | 50 (18-70) | 48 (18-70) | <0.001 |
| Median age at transplant (range), years | 33 (18-58) | 51 (18-70) | 49 (18-70) | <0.001 |
| Male gender, n (%) | 36 (62) | 167 (51) | 203 (52) | 0.12 |
| Median WBC at diagnosis (range), ×103/µL | 33.2 (0.6-280) | 8.7 (0.2-297) | 11.3 (0.2-297) | <0.001 |
| CNS disease, n (%) | 0.005 | |||
| No | 51 (88) | 320 (97) | 371 (96) | |
| Yes | 7 (12) | 9 (3) | 16 (4) | |
| Extramedullary disease, n (%) | 0.001 | |||
| No | 48 (83) | 314 (95) | 362 (94) | |
| Yes | 10 (17) | 15 (5) | 25 (6) | |
| Cytogenetic risk, n (%) | 0.35 | |||
| Favorable | 8 (14) | 23 (7) | 31 (8) | |
| Intermediate | 35 (63) | 204 (66) | 239 (65) | |
| Adverse | 13 (23) | 84 (27) | 97 (26) | |
| Missing | 2 | 18 | 20 | |
| Secondary AML, n (%) | <0.001 | |||
| No | 55 (95) | 248 (75) | 303 (78) | |
| Yes | 3 (5) | 81 (25) | 84 (22) | |
| Median CR duration before HCT (range), days | 69 (7-197) | 108 (11-485) | 98 (7-485) | <0.001 |
| Remission status, n (%) | 0.31 | |||
| First remission | 42 (72) | 258 (78) | 300 (78) | |
| Second remission | 16 (28) | 71 (22) | 87 (22) | |
| Pre-HCT MRD status (by MFC), n (%) | 0.86 | |||
| MRDneg | 47 (81) | 261 (79) | 308 (80) | |
| MRDpos | 11 (19) | 68 (21) | 79 (20) | |
| Recovered peripheral blood counts before HCT*, n (%) | 38 (66) | 252 (77) | 290 (75) | 0.10 |
| Recovered ANC | 48 (83) | 313 (95) | 361 (93) | 0.002 |
| Recovered platelet count | 38 (66) | 253 (77) | 291 (75) | 0.07 |
| Routine karyotyping before HCT, n (%) | 0.10 | |||
| Normalized karyotype | 31 (53) | 130 (40) | 161 (42) | |
| Abnormal karyotype | 9 (16) | 52 (16) | 61 (16) | |
| Missing/non-informative data | 18 (31) | 147 (45) | 165 (43) | |
| Unrelated donor, n (%) | 25 (43) | 222 (67) | 247 (64) | <0.001 |
| Conditioning regimen, n (%) | ||||
| HD-TBI ± CY or FLU | 36 (62) | --- | 36 (9) | |
| HD-TBI/Tepa/FLU | 22 (38) | --- | 22 (6) | |
| BU/CY | --- | 160 (49) | 160 (41) | |
| BU/FLU | --- | 72 (22) | 72 (19) | |
| Treo/FLU ± LD-TBI | --- | 97 (29) | 97 (25) | |
| Stem cell source, n (%) | 0.56 | |||
| PBSC | 51 (88) | 277 (84) | 328 (85) | |
| BM | 7 (12) | 52 (16) | 59 (15) |
*
Absolute neutrophil count ≥1,000/µL and platelets ≥100,000/µL.
Abbreviations: BM, bone marrow; BU, busulfan; CY, cyclophosphamide; FLU, fludarabine; HD-TBI, high-dose total body irradiation; HCT, hematopoietic cell transplantation; LD-TBI, low-dose total body irradiation; MFC, multiparameter flow cytometry; PBSC, peripheral blood stem cells; Tepa; thiotepa; Treo, treosulfan; WBC, white blood cell count.